Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sulfite reduction in mycobacteria.

Rachel Pinto1, Joseph S Harrison, Tsungda Hsu

  • 1Department of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461-1926, USA.

Journal of Bacteriology
|July 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cell Envelope Remodeling and Lipid Metabolism Coordinate Extracellular Vesicle Output in Mycobacterium Tuberculosis.

Journal of extracellular biology·2026
Same author

On the Distribution of Free-Energy in Metabolism.

bioRxiv : the preprint server for biology·2026
Same author

Targeted delivery of the BCG vaccine to dendritic cells improves protective efficacy against Mycobacterium tuberculosis.

Vaccine·2026
Same author

Visualizing early <i>Mycobacterium tuberculosis</i> interactions with murine lung macrophages using intravital imaging.

bioRxiv : the preprint server for biology·2026
Same author

The unique role of <i>nucS</i>-mediated noncanonical mismatch repair in <i>Mycobacterium tuberculosis</i> resistance evolution.

mBio·2025
Same author

Linked-domain inhibitors designed to block UBE2D induce the unfolded protein response.

Cell chemical biology·2025

Mycobacterium tuberculosis sulfur metabolism, specifically sulfite reduction, is essential for bacterial growth and a potential antibiotic target. This study identifies key enzymes and cofactors involved in this unique pathway.

Area of Science:

  • Microbiology
  • Biochemistry
  • Molecular Biology

Background:

  • Mycobacterium tuberculosis poses a significant global health threat.
  • Sulfur metabolism in M. tuberculosis is a promising target for novel antibiotic development due to its unique pathways absent in humans.
  • Sulfite reduction is a critical, bacterium-specific step in mycobacterial sulfur metabolism.

Purpose of the Study:

  • To investigate the essentiality and mechanisms of sulfite reduction in Mycobacterium smegmatis.
  • To characterize the kinetics and substrate specificity of Mycobacterium tuberculosis sulfite reductase.
  • To identify and functionally characterize the gene encoding the ferrochelatase involved in siroheme cofactor synthesis for sulfite reductase.

Main Methods:

  • Deletion mutagenesis to create gene knockouts.

Related Experiment Videos

  • Metabolite screening and enzymatic assays.
  • Purification and characterization of recombinant enzymes.
  • Complementation studies to validate gene function.

    • Main Results:

    • Sulfite reductase (sirA) is essential for growth on sulfate or sulfite; endogenous nitrite-reducing enzymes cannot compensate.
    • Purified M. tuberculosis sulfite reductase exhibits specific sulfite reduction kinetics (kcat = 1.0 s⁻¹, Km = 27 µM) and no nitrite reduction.
    • Rv2393 (che1) encodes a ferrochelatase essential for siroheme synthesis, impacting sulfite reductase activity.
    • Deletion of che1 leads to slow growth, which is partially rescued by optimizing nitrite assimilation, indicating overlapping pathways.

    Conclusions:

    • Sulfite reduction is a vital, non-redundant pathway in mycobacteria, making its enzymes attractive antibiotic targets.
    • The ferrochelatase Che1 plays a crucial role in both sulfur and nitrogen assimilation by supplying the siroheme cofactor.
    • Targeting the sulfite reduction pathway and its associated enzymes presents a viable strategy for developing new anti-tuberculosis drugs.